AstraZeneca gets CDSCO Panel nod to study Palivizumab solution for injection
New Delhi: Citing that clinical trial sites should be geographically distributed, including government sites, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the drug major AstraZeneca to conduct the study of Palivizumab solution for injection 50 mg/0.5 mL and 100 mg/mL.
This came after AstraZeneca presented the proposal to conduct a Phase IV clinical trial titled “A Multicentre, Interventional, Phase IV, Open-label Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease” via Protocol No. D4800L00014 Version 1.0 dated 09 Sep 2024.
Palivizumab is a monoclonal anti-respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients. It works by helping the immune system to slow or stop the spread of the virus in the body. Palivizumab, a recombinant humanized monoclonal antibody that provides passive immunity against RSV, acts by binding the RSV envelope fusion protein (RSV F) on the surface of the virus and blocking a critical step in the membrane fusion process.
Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus (RSV). It belongs to a group of medicines known as immunizing agents. This medicine works by giving your body antibodies to protect it against RSV infection.
At the recent SEC meeting for pulmonary, the expert panel reviewed the proposal presented by AstraZeneca Pharma India to conduct a Phase IV clinical trial titled “A Multicentre, Interventional, Phase IV, Open-label, Study to Evaluate the Safety of Palivizumab in Children Less Than 24 Months of Age With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease”.
After detailed deliberation, the committee recommended conducting the study as per the protocol presented by the firm, with the condition that clinical trial sites should be geographically distributed, including government sites.
Also Read: Exemed Pharmaceutical Gets CDSCO Panel Nod To Study Elobixibat Tablets 5mg
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.